Cargando…

SAT357 Rising Incidence, Health Resource Utilization and Costs of Polycystic Ovary Syndrome in the United Kingdom

Disclosure: T. Berni: None. C. Morgan: None. A. Rees: None. Background: Polycystic Ovary Syndrome (PCOS) is a common disorder but trends in incidence and impact on health resource utilization are not known. Objectives: 1. To describe secular trends in prevalence and incidence of PCOS in the UK. 2. T...

Descripción completa

Detalles Bibliográficos
Autores principales: Berni, Tom, Morgan, Chris, Rees, Aled
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10555218/
http://dx.doi.org/10.1210/jendso/bvad114.1662
_version_ 1785116602946027520
author Berni, Tom
Morgan, Chris
Rees, Aled
author_facet Berni, Tom
Morgan, Chris
Rees, Aled
author_sort Berni, Tom
collection PubMed
description Disclosure: T. Berni: None. C. Morgan: None. A. Rees: None. Background: Polycystic Ovary Syndrome (PCOS) is a common disorder but trends in incidence and impact on health resource utilization are not known. Objectives: 1. To describe secular trends in prevalence and incidence of PCOS in the UK. 2. To establish healthcare resource use and associated primary and secondary care costs. Methods: Data were extracted from the Clinical Practice Research Datalink Aurum database and linked Hospital Episode Statistics (HES) database (2004-2021). Patients (≥18 yrs) of acceptable research quality and eligible for linkage to HES were included. A diagnosis of PCOS was established from medcode or ICD-10 codes. Point prevalence was assessed at the midpoint of each year from 2004-2020. Incident cases (2004-2021) were defined as a first diagnosis (index date) at least 90 days after practice registration. Costs from index date were compared for incident cases (n=132,925) and controls matched (1:1) by age, BMI category and primary care practice. Primary care contacts were assigned an average cost as listed in the Unit Costs of Health and Social Care 2019. Prescription items were assigned a net ingredient cost from the Prescription Cost Analysis for England 2019. Inpatient admissions and outpatient consultations were processed into Healthcare Resource Groups and costed to the National Tariff. Results: The incidence of diagnosed PCOS increased from 1.22 per 1000 person years in 2004 to 1.77 in 2012 and 2.20 in 2019. Point prevalence increased from 0.9% in 2004 to 2.1% in 2012 and 3.4% in 2020. Mean contacts per person year (ppy) for patients with PCOS versus controls were 0.43 vs 0.25 for inpatients (p<0.001), 3.29 vs 1.83 for outpatients (p<0.001) and 6.46 vs 4.71 (p<0.001) for primary care. Mean healthcare costs (ppy) were £748 vs £438 (p<0.001) for inpatients, £383 vs £216 (p<0.001) for outpatients, £156 vs £111 for primary care and £114 vs £87 (p<0.001) for primary care prescriptions. Total health care contacts ppy were 10.81 vs 6.21 (p<0.001) and total associated costs were £1400 vs £852 (p<0.001). Conclusion: The prevalence and incidence of diagnosed PCOS has risen significantly in the United Kingdom over the last two decades. This may be partly due to increased ascertainment and recording on computerised systems. Health resource utilization and costs were almost doubled in women with PCOS compared to controls. Presentation Date: Saturday, June 17, 2023
format Online
Article
Text
id pubmed-10555218
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-105552182023-10-06 SAT357 Rising Incidence, Health Resource Utilization and Costs of Polycystic Ovary Syndrome in the United Kingdom Berni, Tom Morgan, Chris Rees, Aled J Endocr Soc Reproductive Endocrinology Disclosure: T. Berni: None. C. Morgan: None. A. Rees: None. Background: Polycystic Ovary Syndrome (PCOS) is a common disorder but trends in incidence and impact on health resource utilization are not known. Objectives: 1. To describe secular trends in prevalence and incidence of PCOS in the UK. 2. To establish healthcare resource use and associated primary and secondary care costs. Methods: Data were extracted from the Clinical Practice Research Datalink Aurum database and linked Hospital Episode Statistics (HES) database (2004-2021). Patients (≥18 yrs) of acceptable research quality and eligible for linkage to HES were included. A diagnosis of PCOS was established from medcode or ICD-10 codes. Point prevalence was assessed at the midpoint of each year from 2004-2020. Incident cases (2004-2021) were defined as a first diagnosis (index date) at least 90 days after practice registration. Costs from index date were compared for incident cases (n=132,925) and controls matched (1:1) by age, BMI category and primary care practice. Primary care contacts were assigned an average cost as listed in the Unit Costs of Health and Social Care 2019. Prescription items were assigned a net ingredient cost from the Prescription Cost Analysis for England 2019. Inpatient admissions and outpatient consultations were processed into Healthcare Resource Groups and costed to the National Tariff. Results: The incidence of diagnosed PCOS increased from 1.22 per 1000 person years in 2004 to 1.77 in 2012 and 2.20 in 2019. Point prevalence increased from 0.9% in 2004 to 2.1% in 2012 and 3.4% in 2020. Mean contacts per person year (ppy) for patients with PCOS versus controls were 0.43 vs 0.25 for inpatients (p<0.001), 3.29 vs 1.83 for outpatients (p<0.001) and 6.46 vs 4.71 (p<0.001) for primary care. Mean healthcare costs (ppy) were £748 vs £438 (p<0.001) for inpatients, £383 vs £216 (p<0.001) for outpatients, £156 vs £111 for primary care and £114 vs £87 (p<0.001) for primary care prescriptions. Total health care contacts ppy were 10.81 vs 6.21 (p<0.001) and total associated costs were £1400 vs £852 (p<0.001). Conclusion: The prevalence and incidence of diagnosed PCOS has risen significantly in the United Kingdom over the last two decades. This may be partly due to increased ascertainment and recording on computerised systems. Health resource utilization and costs were almost doubled in women with PCOS compared to controls. Presentation Date: Saturday, June 17, 2023 Oxford University Press 2023-10-05 /pmc/articles/PMC10555218/ http://dx.doi.org/10.1210/jendso/bvad114.1662 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of the Endocrine Society. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Reproductive Endocrinology
Berni, Tom
Morgan, Chris
Rees, Aled
SAT357 Rising Incidence, Health Resource Utilization and Costs of Polycystic Ovary Syndrome in the United Kingdom
title SAT357 Rising Incidence, Health Resource Utilization and Costs of Polycystic Ovary Syndrome in the United Kingdom
title_full SAT357 Rising Incidence, Health Resource Utilization and Costs of Polycystic Ovary Syndrome in the United Kingdom
title_fullStr SAT357 Rising Incidence, Health Resource Utilization and Costs of Polycystic Ovary Syndrome in the United Kingdom
title_full_unstemmed SAT357 Rising Incidence, Health Resource Utilization and Costs of Polycystic Ovary Syndrome in the United Kingdom
title_short SAT357 Rising Incidence, Health Resource Utilization and Costs of Polycystic Ovary Syndrome in the United Kingdom
title_sort sat357 rising incidence, health resource utilization and costs of polycystic ovary syndrome in the united kingdom
topic Reproductive Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10555218/
http://dx.doi.org/10.1210/jendso/bvad114.1662
work_keys_str_mv AT bernitom sat357risingincidencehealthresourceutilizationandcostsofpolycysticovarysyndromeintheunitedkingdom
AT morganchris sat357risingincidencehealthresourceutilizationandcostsofpolycysticovarysyndromeintheunitedkingdom
AT reesaled sat357risingincidencehealthresourceutilizationandcostsofpolycysticovarysyndromeintheunitedkingdom